MARIETTA, Ga., May 26, 2016 /PRNewswire/ -- MiMedx Group,
Inc. (NASDAQ: MDXG), the leading regenerative medicine company
utilizing human amniotic membrane and other birth tissues, human
skin and bone, and patent-protected processes and proprietary
platforms to develop and market advanced products and therapies,
announced today that it will present at the Jefferies 2016 Global
Healthcare Conference in New York,
New York. Parker H. "Pete" Petit, Chairman and CEO,
Michael J. Senken, Chief Financial
Officer, and Christopher M. Cashman,
EVP and Chief Commercialization Officer, are scheduled to present
on Wednesday, June 8th at
4:30 p.m. eastern time, at the Grand
Hyatt New York. A webcast of this presentation will be
available on the Company's website, www.mimedx.com.
About MiMedx
MiMedx® is an integrated developer,
processor and marketer of patent protected and proprietary
regenerative biomaterial products and bioimplants processed from
human amniotic membrane and other birth tissues and human skin and
bone. "Innovations in Regenerative
Biomaterials" is the framework behind our mission to give
physicians products and tissues to help the body heal itself.
Our biomaterial platform technologies are AmnioFix®, EpiFix®,
OrthoFlo, Physio®, AlloBurn™, and CollaFix™. AmnioFix and EpiFix
are our tissue technologies processed from human amniotic membrane
derived from donated placentas. Elected in advance of delivery
through our donor program, a mother delivering a healthy baby via
scheduled full-term Caesarean section birth may donate the placenta
in lieu of having it discarded as medical waste. We process
the human amniotic membrane utilizing our proprietary PURION®
Process, to produce a safe and effective implant. MiMedx is the
leading supplier of amniotic tissue, having supplied over 600,000
allografts to date for application in the Wound Care, Burn,
Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental
sectors of healthcare. We recently introduced OrthoFlo, an
amniotic fluid derived allograft for homologous use. Amniotic
fluid is donated by a consenting mother delivering a full-term
healthy baby by scheduled Caesarean section. Through the
recent acquisition of Stability Biologics, our newest
proprietary platforms include Physio™, a unique bone grafting
material comprised of 100% bone tissue with no added carrier, thus
maximizing bone forming potential, a demineralized bone
matrix (DBM) to complement our product portfolio offerings within
the Orthopedic market and AlloBurn, a skin product for burns.
CollaFix, our next technology platform we plan to commercialize, is
our collagen fiber technology, developed with our patented
cross-linking polymers, designed to mimic the natural composition,
structure and mechanical properties of musculoskeletal tissues in
order to augment their repair. CollaFix is the only
biological, biodegradable, biomimetic technology that matches human
tendon in strength and stiffness. The Company's wholly-owned
subsidiary, Stability Biologics, LLC, is accredited by the American
Association of Tissue Banks (AATB) and registered with the FDA. The
Company distinguishes its revenue in two primary regenerative
medicine specialties of "Wound Care" and "SSO." The Company
defines SSO as surgical, sports medicine and orthopedics with
spinal procedures included in orthopedics and abdominal, and lower
pelvic procedures included in surgical.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mimedx-to-present-at-the-jefferies-2016-global-healthcare-conference-300275744.html
SOURCE MiMedx Group, Inc.